IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v20y2023i4p3695-d1073674.html
   My bibliography  Save this article

A Critical Appraisal of the Diagnostic and Prognostic Utility of the Anti-Inflammatory Marker IL-37 in a Clinical Setting: A Case Study of Patients with Diabetes Type 2

Author

Listed:
  • Zvonimir Bosnić

    (Department of Family Medicine, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Huttlerova 4, 31000 Osijek, Croatia)

  • František Babič

    (Department of Cybernetics and Artificial Intelligence, Faculty of Electrical Engineering and Informatics, Technical University of Košice, 06601 Košice, Slovakia)

  • Viera Anderková

    (Department of Cybernetics and Artificial Intelligence, Faculty of Electrical Engineering and Informatics, Technical University of Košice, 06601 Košice, Slovakia)

  • Mario Štefanić

    (Department of Nuclear Medicine, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Huttlerova 4, 31000 Osijek, Croatia)

  • Thomas Wittlinger

    (Department of Cardiology, Asklepios Hospital, University of Göttingen, 38642 Goslar, Germany)

  • Ljiljana Trtica Majnarić

    (Department of Family Medicine, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Huttlerova 4, 31000 Osijek, Croatia)

Abstract

Background: The role of the cytokine interleukin-37 (IL-37) has been recognized in reversing inflammation-mediated metabolic costs. The aim was to evaluate the clinical utility of this cytokine as a diagnostic and prognostic marker in patients with type 2 diabetes (T2D). Methods: We included 170 older (median: 66 years) individuals with T2D (females: 95) and classified as primary care attenders to assess the association of factors that describe patients with plasma IL-37 levels (expressed as quartiles) using multinomial regression models. We determined the diagnostic ability of IL-37 cut-offs to identify diabetes-related complications or patient subgroups by using Receiver Operating Characteristic analysis (c-statistics). Results: Frailty status was shown to have a suppressive effect on IL-37 circulating levels and a major modifying effect on associations of metabolic and inflammatory factors with IL-37, including the effects of treatments. Situations in which IL-37 reached a clinically significant discriminating ability included the model of IL-37 and C-Reactive Protein in differentiating among diabetic patients with low–normal/high BMI ((<25/≥25 kg/m 2 ), and the model of IL-37 and Thyroid Stimulating Hormone in discriminating between women with/without metabolic syndrome. Conclusions: The study has revealed limitations in using classical approaches in determining the diagnostic and prognostic utility of the cytokine IL-37 in patients with T2D and lain a foundation for new methodology approaches.

Suggested Citation

  • Zvonimir Bosnić & František Babič & Viera Anderková & Mario Štefanić & Thomas Wittlinger & Ljiljana Trtica Majnarić, 2023. "A Critical Appraisal of the Diagnostic and Prognostic Utility of the Anti-Inflammatory Marker IL-37 in a Clinical Setting: A Case Study of Patients with Diabetes Type 2," IJERPH, MDPI, vol. 20(4), pages 1-19, February.
    • Handle: RePEc:gam:jijerp:v:20:y:2023:i:4:p:3695-:d:1073674
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/20/4/3695/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/20/4/3695/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Michael Roden & Gerald I. Shulman, 2019. "The integrative biology of type 2 diabetes," Nature, Nature, vol. 576(7785), pages 51-60, December.
    2. Cheng Han & Xue He & Xinghai Xia & Yongze Li & Xiaoguang Shi & Zhongyan Shan & Weiping Teng, 2015. "Subclinical Hypothyroidism and Type 2 Diabetes: A Systematic Review and Meta-Analysis," PLOS ONE, Public Library of Science, vol. 10(8), pages 1-22, August.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Emmanouela Tsagkaraki & Sarah M. Nicoloro & Tiffany DeSouza & Javier Solivan-Rivera & Anand Desai & Lawrence M. Lifshitz & Yuefei Shen & Mark Kelly & Adilson Guilherme & Felipe Henriques & Nadia Amran, 2021. "CRISPR-enhanced human adipocyte browning as cell therapy for metabolic disease," Nature Communications, Nature, vol. 12(1), pages 1-17, December.
    2. Shaza B. Zaghlool & Anna Halama & Nisha Stephan & Valborg Gudmundsdottir & Vilmundur Gudnason & Lori L. Jennings & Manonanthini Thangam & Emma Ahlqvist & Rayaz A. Malik & Omar M. E. Albagha & Abdul Ba, 2022. "Metabolic and proteomic signatures of type 2 diabetes subtypes in an Arab population," Nature Communications, Nature, vol. 13(1), pages 1-17, December.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:20:y:2023:i:4:p:3695-:d:1073674. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.